表 1. Analysis of the degree of EEG slowing, δ brush and the clinical data of anti-NMDARE.
脑电背景活动慢化异常程度、δ刷与抗NMDA受体脑炎临床资料的分析结果
| Clinical data | Normal EEG (n=7) | Mildly abnormal EEG (n=25) | Moderately abnormal EEG (n=11) | Severely abnormal EEG (n=9) | Z | P | With δ brush (n=46) | Without δ brush (n=6) | χ 2 | P |
| Male (n=18) | 3 (43%) | 10 (40%) | 2 (18%) | 3 (33%) | −0.927 | 0.354 | 16 | 2 | 0.005 | 0.944 |
| Adult (≥18 yr.) (n=40) | 6 (86%) | 21 (84%) | 8 (73%) | 5 (56%) | −1.674 | 0.094 | 36 | 4 | 0.402 | 0.526 |
| Severe illness (n=24) | 1 (14%) | 8 (32%) | 6 (55%) | 9 (100%) | −3.695 | 0.001 | 18 | 6 | 7.913 | 0.005 |
| ICU admisson (n=5) | 0 | 0 | 2 (18%) | 3 (33%) | −2.908 | 0.004 | 2 | 3 | 12.728 | <0.001 |
| CSF antibody titer>1∶10 (n=22) | 2 (29%) | 8 (32%) | 6 (55%) | 6 (67%) | −2.104 | 0.035 | 18 | 4 | 1.535 | 0.215 |
| Abnormal MRI (n=21) | 3 (43%) | 10 (40%) | 3 (27%) | 5 (56%) | −0.190 | 0.850 | 19 | 2 | 0.140 | 0.708 |
| Comorbid tumors (n=4) | 0 | 1 (4%) | 1 (9%) | 2 (22%) | −1.765 | 0.078 | 2 | 2 | 6.280 | 0.012 |
| Second-line immunotherapy (n=7) | 0 | 1 (4%) | 3 (27%) | 3 (33%) | −2.660 | 0.008 | 5 | 2 | 2.299 | 0.129 |
| Poor prognosis (n=7) | 0 | 1 (4%) | 2(18%) | 4 (44%) | −2.943 | 0.003 | 4 | 3 | 7.773 | 0.005 |